Dokter Dorofey, acute geneeskunde
0828.644.373 · rovalta.com · 26/09/2026
Dokter Dorofey, acute geneeskunde
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBODokter Dorofey, acute geneeskunde is a Private company with limited liability incorporated in 2010. Its main activity is: Specialist medical practice activities. Its registered office is in Aartselaar.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0828.644.373
- Incorporation
- 20/08/2010
- Legal form
- Private company with limited liability
- Registered office
- Karel Van de Woestijnelaan 2
2630 Aartselaar · FlandreSee on map - Contributed capital
- 18 600,00 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 16 filingsTrend over 16 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 529,2 k € | +29.1% | 410 k € | +10.3% | 371,8 k € | -5.8% | 394,8 k € | +63.5% | 241,5 k € |
| EBITDA | 523,7 k € | +38.3% | 378,7 k € | +2.5% | 369,4 k € | +0.1% | 369,1 k € | +68.3% | 219,3 k € |
| Operating result | 462,8 k € | +45.8% | 317,4 k € | +49.0% | 213 k € | -33.5% | 320,6 k € | +90.4% | 168,4 k € |
| Net result | 311,1 k € | +34.4% | 231,6 k € | +50.9% | 153,5 k € | -28.3% | 214,1 k € | +95.8% | 109,3 k € |
| Balance sheet | |||||||||
| Equity | 1,1 M € | -9.7% | 1,2 M € | +10.6% | 1,1 M € | -5.5% | 1,1 M € | +9.6% | 1 M € |
| Total assets | 1,9 M € | +34.2% | 1,4 M € | +13.0% | 1,3 M € | -27.9% | 1,8 M € | +9.0% | 1,6 M € |
| Cash | 0 € | 0.0% | 0 € | -100.0% | 8,3 k € | -28.7% | 11,7 k € | -40.7% | 19,7 k € |
| Debts | 864,3 k € | +232% | 260,6 k € | +25.4% | 207,7 k € | -67.3% | 635,6 k € | +7.9% | 589 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20251 active · 2 ended
Active mandates
Ended mandates
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 28/08/2026 | 18/09/2025 | 27/09/2024 | 21/08/2023 | 30/09/2022 | 30/09/2021 |
| General meeting | 30/05/2026 | 31/05/2025 | 25/05/2024 | 27/05/2023 | 28/05/2022 | 29/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 16 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2025 | 30/05/2026 | 28/08/2026 | Dutch | |
| Micro model | 31/12/2024 | 31/05/2025 | 18/09/2025 | Dutch | |
| Micro model | 31/12/2023 | 25/05/2024 | 27/09/2024 | Dutch | |
| Micro model | 31/12/2022 | 27/05/2023 | 21/08/2023 | Dutch | |
| Micro model | 31/12/2021 | 28/05/2022 | 30/09/2022 | Dutch | |
| Micro model | 31/12/2020 | 29/05/2021 | 30/09/2021 | Dutch | |
| Micro model | 31/12/2019 | 30/05/2020 | 16/11/2020 | Dutch | |
| Micro model | 31/12/2018 | 25/05/2019 | 28/08/2019 | Dutch | |
| Micro model | 31/12/2017 | 26/05/2018 | 27/09/2018 | Dutch | |
| Micro model | 31/12/2016 | 27/05/2017 | 01/08/2017 | Dutch | |
| Abridged model | 31/12/2015 | 28/05/2016 | 30/06/2016 | Dutch | |
| Abridged model | 31/12/2014 | 27/06/2015 | 31/07/2015 | Dutch | |
| Abridged model | 31/12/2013 | 01/03/2014 | 04/07/2014 | Dutch | |
| Abridged model | 31/12/2012 | 09/03/2013 | 18/06/2013 | Dutch | |
| Abridged model | 31/12/2011 | 10/03/2012 | 12/06/2012 | Dutch | |
| Abridged model | 31/12/2010 | 28/05/2011 | 27/07/2011 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active · 2 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025311,1 k €↑
- 2024Annual accounts 2024231,6 k €↑
- 2024Name changeDokter Dorofey, acute geneeskunde
- 2023Annual accounts 2023153,5 k €↓
- 2022Annual accounts 2022214,1 k €↑
- 2021Annual accounts 2021109,3 k €↑
- 2021Name changeDokter DOROFEY, acute geneesk.
- 2020Annual accounts 2020104,1 k €↓
- 2019Annual accounts 2019119,9 k €↓
- 2018Annual accounts 2018215,5 k €↑
- 2017Annual accounts 2017165,9 k €↑
- 2016Annual accounts 2016144 k €↑
- 2015Annual accounts 2015121,5 k €↓
- 2014Annual accounts 2014133,7 k €↑
- 2013Annual accounts 2013122,5 k €↑
- 2012Annual accounts 201245,4 k €↓
- 2011Annual accounts 201175,2 k €↑
- 2010Annual accounts 201051,2 k €
- 20/08/2010IncorporationPrivate company with limited liability